Subsidiary Companies: Tego BioSciences

Tego BioSciences has extensive foundational intellectual property relating to fullerene synthesis and modification for therapeutic purposes and key patents that are critical in making fullerenes into useable products.

Tego is seeking to monetize its proprietary compounds and enabling patents through a licensing and partnership model with a primary focus on establishing partnerships in the areas of MRI contrast agents and treatment of neurodegenerative conditions.

Tego is a wholly owned subsidiary of Arrowhead Research (Nasdaq: ARWR).